CR20110115A - Metodos para tratar la talasemia - Google Patents
Metodos para tratar la talasemiaInfo
- Publication number
- CR20110115A CR20110115A CR20110115A CR20110115A CR20110115A CR 20110115 A CR20110115 A CR 20110115A CR 20110115 A CR20110115 A CR 20110115A CR 20110115 A CR20110115 A CR 20110115A CR 20110115 A CR20110115 A CR 20110115A
- Authority
- CR
- Costa Rica
- Prior art keywords
- talasemia
- treat
- methods
- thalassemia
- symptom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
En la presente invenci´n se proporciona un método para tratar, meejorar, o retrasar al menos de un síntoma de un transtorno sanguíneo genético, por ejemplo, anemia drepanocítica o talasemia, en un paciente que lo necesite, que comprende administrar una cantidad terapéuticamnete eficaz de un inhibidor de Jak2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8623308P | 2008-08-05 | 2008-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110115A true CR20110115A (es) | 2011-06-03 |
Family
ID=41581108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110115A CR20110115A (es) | 2008-08-05 | 2011-03-02 | Metodos para tratar la talasemia |
Country Status (20)
Country | Link |
---|---|
US (1) | US20110269721A1 (es) |
EP (1) | EP2355827A2 (es) |
JP (1) | JP2011530517A (es) |
KR (1) | KR20110053347A (es) |
CN (1) | CN102112131A (es) |
AU (1) | AU2009279825A1 (es) |
BR (1) | BRPI0917575A2 (es) |
CA (1) | CA2732791A1 (es) |
CL (1) | CL2011000242A1 (es) |
CO (1) | CO6351728A2 (es) |
CR (1) | CR20110115A (es) |
DO (1) | DOP2011000044A (es) |
EC (1) | ECSP11010847A (es) |
IL (1) | IL211061A0 (es) |
MA (1) | MA32611B1 (es) |
MX (1) | MX2011001426A (es) |
NI (1) | NI201100031A (es) |
RU (1) | RU2011108563A (es) |
SV (1) | SV2011003823A (es) |
WO (1) | WO2010017122A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1809614B1 (en) | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
CA2578283A1 (en) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
NZ611654A (en) * | 2010-12-03 | 2015-08-28 | Ym Biosciences Australia Pty | Treatment of jak2-mediated conditions |
PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
CN103664799A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
EP2970205B1 (en) * | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
MA44666A (fr) * | 2016-04-15 | 2019-02-20 | Epizyme Inc | Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2 |
WO2018183923A1 (en) * | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
AU2018254577A1 (en) | 2017-04-21 | 2019-12-05 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
CA3079412A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
JP2021524835A (ja) | 2018-04-05 | 2021-09-16 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Axlキナーゼ阻害剤およびその使用 |
MX2020010556A (es) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
WO2020051571A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
CN112778282B (zh) | 2021-01-06 | 2022-07-22 | 温州医科大学 | 一种嘧啶类小分子化合物及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
-
2009
- 2009-08-03 CA CA2732791A patent/CA2732791A1/en not_active Abandoned
- 2009-08-03 BR BRPI0917575A patent/BRPI0917575A2/pt not_active IP Right Cessation
- 2009-08-03 JP JP2011522136A patent/JP2011530517A/ja active Pending
- 2009-08-03 MX MX2011001426A patent/MX2011001426A/es not_active Application Discontinuation
- 2009-08-03 AU AU2009279825A patent/AU2009279825A1/en not_active Abandoned
- 2009-08-03 WO PCT/US2009/052544 patent/WO2010017122A2/en active Application Filing
- 2009-08-03 RU RU2011108563/15A patent/RU2011108563A/ru not_active Application Discontinuation
- 2009-08-03 US US13/057,133 patent/US20110269721A1/en not_active Abandoned
- 2009-08-03 KR KR1020117005224A patent/KR20110053347A/ko not_active Application Discontinuation
- 2009-08-03 CN CN2009801303954A patent/CN102112131A/zh active Pending
- 2009-08-03 EP EP09741504A patent/EP2355827A2/en not_active Withdrawn
-
2011
- 2011-02-01 SV SV2011003823A patent/SV2011003823A/es not_active Application Discontinuation
- 2011-02-02 NI NI201100031A patent/NI201100031A/es unknown
- 2011-02-03 IL IL211061A patent/IL211061A0/en unknown
- 2011-02-03 DO DO2011000044A patent/DOP2011000044A/es unknown
- 2011-02-04 CL CL2011000242A patent/CL2011000242A1/es unknown
- 2011-02-28 EC EC2011010847A patent/ECSP11010847A/es unknown
- 2011-03-02 CR CR20110115A patent/CR20110115A/es not_active Application Discontinuation
- 2011-03-04 MA MA33672A patent/MA32611B1/fr unknown
- 2011-03-04 CO CO11026653A patent/CO6351728A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2732791A1 (en) | 2010-02-11 |
RU2011108563A (ru) | 2012-09-10 |
KR20110053347A (ko) | 2011-05-20 |
WO2010017122A3 (en) | 2010-04-08 |
JP2011530517A (ja) | 2011-12-22 |
NI201100031A (es) | 2011-09-26 |
SV2011003823A (es) | 2011-08-15 |
IL211061A0 (en) | 2011-04-28 |
EP2355827A2 (en) | 2011-08-17 |
BRPI0917575A2 (pt) | 2019-09-24 |
ECSP11010847A (es) | 2011-07-29 |
AU2009279825A1 (en) | 2010-02-11 |
MA32611B1 (fr) | 2011-09-01 |
CO6351728A2 (es) | 2011-12-20 |
DOP2011000044A (es) | 2011-04-30 |
CN102112131A (zh) | 2011-06-29 |
WO2010017122A2 (en) | 2010-02-11 |
MX2011001426A (es) | 2011-03-21 |
US20110269721A1 (en) | 2011-11-03 |
CL2011000242A1 (es) | 2011-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110115A (es) | Metodos para tratar la talasemia | |
CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
AR055038A1 (es) | Metodo y compuesto para tratar enfermedades vasculares perifericas | |
EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
ECSP11010971A (es) | Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un fármaco oral o no oral antidiabético | |
UY32062A (es) | Inhibidores de beta-secretasa | |
WO2013024282A3 (en) | Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer | |
EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
EA201391578A1 (ru) | Способы лечения рассеянного склероза и сохранения и/или увеличения содержания миелина | |
BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
BR112013028420A2 (pt) | tratamento de mieloma múltiplo | |
EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
BR112013004850A2 (pt) | tratamento de infarto do miocárdio usando antagonistas tgf-beta | |
EA202091676A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
CR11605A (es) | Tratamiento de plantas ornamentales | |
EA201490614A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB | |
UA106214C2 (ru) | Ингибиторы митоза для интенсификации процесса апоптоза при терапии | |
WO2010026213A3 (en) | Treatment of scleroderma | |
WO2011104412A3 (es) | Compuestos para el tratamiento de alzheimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |